Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele

Chikata, Takayuki; Kuse, Nozomi; Murakoshi, Hayato; Gatanaga, Hiroyuki; Oka, Shinichi; Takiguchi, Masafumi

doi:10.1128/jvi.01248-22

Cited by 4 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protective role of HLAs against bacteria [112], parasites [113], and even viruses is well reported. Their role in fighting viruses like HIV [114], HCV [115], HBV [116], and SARS [8,[26][27][28][29][30][31][32][33][34][35][36][117][118][119] have been documented. Interestingly, the protective role of the CD-associated HLA II suggested by Greco N et al [23] represents a refreshing new idea that can help in our understanding of the celiac-COVID-19-HLA axis.…”

Section: Discussionmentioning

confidence: 99%

HLA-DQ2/8 and COVID-19 in Celiac Disease: Boon or Bane

Lerner,

Benzvi,

Vojdani

2023

Microorganisms

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic continues to pose a global threat. While its virulence has subsided, it has persisted due to the continual emergence of new mutations. Although many high-risk conditions related to COVID-19 have been identified, the understanding of protective factors remains limited. Intriguingly, epidemiological evidence suggests a low incidence of COVID-19-infected CD patients. The present study explores whether their genetic background, namely, the associated HLA-DQs, offers protection against severe COVID-19 outcomes. We hypothesize that the HLA-DQ2/8 alleles may shield CD patients from SARS-CoV-2 and its subsequent effects, possibly due to memory CD4 T cells primed by previous exposure to human-associated common cold coronaviruses (CCC) and higher affinity to those allele’s groove. In this context, we examined potential cross-reactivity between SARS-CoV-2 epitopes and human-associated CCC and assessed the binding affinity (BA) of these epitopes to HLA-DQ2/8. Using computational methods, we analyzed sequence similarity between SARS-CoV-2 and four distinct CCC. Of 924 unique immunodominant 15-mer epitopes with at least 67% identity, 37 exhibited significant BA to HLA-DQ2/8, suggesting a protective effect. We present various mechanisms that might explain the protective role of HLA-DQ2/8 in COVID-19-afflicted CD patients. If substantiated, these insights could enhance our understanding of the gene–environment enigma and viral–host relationship, guiding potential therapeutic innovations against the ongoing SARS-CoV-2 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

HLA-DQ2/8 and COVID-19 in Celiac Disease: Boon or Bane

Lerner,

Benzvi,

Vojdani

2023

Microorganisms

View full text Add to dashboard Cite

show abstract

“…Because immune-checkpoint inhibitors are a relatively new type of cancer treatment, long-term data on their efficacy and potential side effects is also lacking. This topic was previously described by other authors [114][115][116][117]. Immune-checkpoint inhibition can be used to treat various malignancies including melanoma, lung cancer, bladder cancer, kidney cancer, and Hodgkin's lymphoma.…”

Section: Presents the Mutual Regulation By Various Immune Checkpoints...mentioning

confidence: 90%

Recent Advances in Molecular Mechanisms of Cancer Immunotherapy

Kciuk

Yahya

Mohamed

et al. 2023

Cancers

View full text Add to dashboard Cite

Cancer is among the current leading causes of death worldwide, despite the novel advances that have been made toward its treatment, it is still considered a major public health concern. Considering both the serious impact of cancer on public health and the significant side effects and complications of conventional therapeutic options, the current strategies towards targeted cancer therapy must be enhanced to avoid undesired toxicity. Cancer immunotherapy has become preferable among researchers in recent years compared to conventional therapeutic options, such as chemotherapy, surgery, and radiotherapy. The understanding of how to control immune checkpoints, develop therapeutic cancer vaccines, genetically modify immune cells as well as enhance the activation of antitumor immune response led to the development of novel cancer treatments. In this review, we address recent advances in cancer immunotherapy molecular mechanisms. Different immunotherapeutic approaches are critically discussed, focusing on the challenges, potential risks, and prospects involving their use.

show abstract

HLA-B*57:01 genotype and Abacavir therapy: first report from genomic lab in AORN dei Colli Naples -Italy

Maddaloni,

Pompeis,

Pepe

et al. 2024

JSRT

View full text Add to dashboard Cite

AIDS (acquired immunodeficiency syndrome) is an infectious disease caused by the HIV virus (human immunodeficiency virus). The core of HIV treatment is antiretroviral therapy (ART). Abacavir, an antiretroviral drug used to treat HIV infections, is widely used in the treatment of HIV-supported infections. The active ingredient of the drug is not able to completely eradicate the infection, leading to a patient’s recovery, but it reduces the amount of virus in the body, keeping it at low levels. Pharmacogenetic tests are used in clinical practice to optimize the choice of medication or clinical management of the patient. Before starting treatment, it is necessary to perform a genetic exam to assess the presence of the HLA allele B57:01. Patients with the HLA B57:01 allele are therefore at increased risk of hypersensitivity to Abacavir. An adverse effect of abacavir is a hypersensitivity reaction, which can be severe and potentially life-threatening, and may limit treatment with the drug. The abacavir-induced hypersensitivity reaction was therefore associated with the presence of the class I allele of the major histocompatibility complex HLA-B*5701. Screening patients for HLA-B*57:01 before starting abacavir therapy reduces the incidence of hypersensitivity reactions. The study we carried out aims to evaluate the presence of the HLAB57:01 allele in the HIV-positive population present in our territory.

show abstract

Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele

Cited by 4 publications

References 80 publications

HLA-DQ2/8 and COVID-19 in Celiac Disease: Boon or Bane

HLA-DQ2/8 and COVID-19 in Celiac Disease: Boon or Bane

Recent Advances in Molecular Mechanisms of Cancer Immunotherapy

HLA-B*57:01 genotype and Abacavir therapy: first report from genomic lab in AORN dei Colli Naples -Italy

Contact Info

Product

Resources

About